
Thursday, June 09, 2022 4:51:12 PM
Report #1: https://drive.google.com/file/d/1Nt4BJURr0psZ6QkM7UX77TCZI1IJdNSJ/view
Report #2: https://drive.google.com/file/d/1ojb1BbftmDH6VKLRA8GM6gCeB4ulLoLp/view?usp=sharing

Liked By
Spread the love. Be the first to like this post!
Recent ANVS News
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/08/2023 10:12:56 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:44:43 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:43:38 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:41:48 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:41:47 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:40:33 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/06/2023 09:06:37 PM
- Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team • PR Newswire (US) • 01/06/2023 12:30:00 PM
- Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update • PR Newswire (US) • 11/08/2022 10:35:00 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/08/2022 09:45:41 PM
- Annovis Bio to Present at the 2022 ThinkEquity Investor Conference • PR Newswire (US) • 10/20/2022 11:30:00 AM
- Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease • PR Newswire (US) • 10/11/2022 11:30:00 AM
- H.C. Wainwright Sticks to Its Buy Rating for Annovis Bio (ANVS) • TipRanks • 10/11/2022 08:46:40 AM
- Annovis Bio Shares Rise 6% After FDA Approves Buntanetap Study • Dow Jones News • 10/06/2022 02:34:00 PM
- Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease • PR Newswire (US) • 10/06/2022 11:30:00 AM
- Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference • PR Newswire (US) • 09/29/2022 11:30:00 AM
- Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases • PR Newswire (US) • 09/13/2022 11:30:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 09/12/2022 09:10:14 PM
- Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders • PR Newswire (US) • 09/08/2022 11:30:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/30/2022 10:05:03 AM
- Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer • PR Newswire (US) • 08/29/2022 08:00:00 PM
- Annovis Bio (ANVS) Gets a Buy from Maxim Group • TipRanks • 08/25/2022 01:45:21 PM
- Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease • PR Newswire (US) • 08/24/2022 11:30:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/08/2022 12:31:32 PM
- Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update • PR Newswire (US) • 08/08/2022 11:30:00 AM
Metatron Releases All-in-One Artificial Intelligence Mobile Apps for iPhone and Android • MRNJ • Mar 27, 2023 9:00 AM
Memorandum of Understanding With Miranda Water Treatment Systems and Rainmaker Worldwide Inc. Extended • RAKR • Mar 27, 2023 8:50 AM
Hollywall Entertainment Inc., (OTC:HWAL) Announces the completion of its 2021 and 2020 Audit (s) • HWAL • Mar 24, 2023 12:48 PM
Glucose Health, Inc. Fiscal 2022 Annual Report • GLUC • Mar 23, 2023 3:23 PM
Nextech3D.ai Announces Its AI-Powered SaaS Platform Toggle3D Experiences A +963% Jump in Users in 60-Days Crossing Over 1000 Users • NTAR • Mar 23, 2023 7:07 AM
Lifecycle Assessment by Benchmark Shows TMC's NORI-D Nodule Project Could Outperform Land-Based Routes of Producing Nickel, Copper and Cobalt in Almost Every Impact Category Analyzed • TMC • Mar 22, 2023 1:44 PM